Skip to main content

1 Result(s)

within Bing-qi Hu Remove this filter

and

  1. Article

    Open Access

    B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors

    Not all lung adenocarcinoma (LUAD) patients with activating epidermal growth factor receptor (EGFR) mutations respond to tyrosine kinase inhibitors (TKIs) as intended. Thus, biomarkers are needed to identify pati...

    Ying Yang, Jun-feng Huang, Bing-qi Hu, **g Zhou… in World Journal of Surgical Oncology (2022)

    Download PDF (1264 KB) View Article